In this work, the effect of two broadly-active PKC inhibitors, calphostin C, a potent inhibitor used in the treatment of some cancer cell lines [42,43], and chelerythrine, with broad-spectrum biological activities, such as antimicrobial, antifungal, anti-inflammatory, and anti-tumoral effects [44], and two PKC inhibitors that have shown specific activity against conventional and novel PKC isoforms, sotrastaurine and enzastaurin, have been assayed against WNV infection in cell culture. This evidence concerns the gene PRRT2 and cancer.